Abstract
Drug induced liver disease (DILD) is common and of difficult diagnosis. To report the clinical, laboratory and pathological findings in 33 patients with DILD. We revised 1,164 liver biopsies and 57 were selected as suspicious of DILD. In these, the scale proposed by Maria et al was applied to assess the possibility of hepatotoxicity reactions and 33 were selected. The 33 cases had a mean age of 48 +/- 18 years and 14 were male. Forty eight medications were involved, with an average of 1.4 drugs per patient. The main drugs were antimicrobials, antineoplastics-immunosuppressives and non-steroidal antiinflammatory drugs. The clinical presentations in order of frequency were cholestasis, hepatitis, asymptomatic, fulminant hepatitis and cirrhosis. The laboratory alterations observed in cases with hepatitis were 20 fold transaminase and bilirubin elevation. In cholestasis, moderate elevations of alkaline phosphatases and gamma glytamyl transferase were observed. Pathology showed hepatocellular damage, cholestasis and mixed damage, but also submassive necrosis and cirrhosis in one case. The present study confirms that DILD is frequently unpredictable and that it can cause a wide variety of clinical and pathological presentations, that can even evolve to chronicity.
Highlights
Drug induced liver disease (DILD) is common and of difficult diagnosis
In these, the scale proposed by Maria et al was applied to assess the possibility of hepatotoxicity reactions
The 33 cases had a mean age of 48±18 years
Summary
Drug induced liver disease (DILD) is common and of difficult diagnosis. Aim: To report the clinical, laboratory and pathological findings in 33 patients with DILD. Esta asigna puntaje a la relación temporal entre la ingesta del fármaco y a la reacción hepatotóxica, a la exclusión de causas alternativas de daño hepático, a manifestaciones extrahepáticas, a reexposición intencional o accidental a la droga y a la información previa en la literatura de la hepatotoxicidad atribuida a ese fármaco en particular. Se registraron todos los fármacos que potencialmente estaban en relación al daño hepático, considerando dosis, tiempo de consumo y perfil de presentación temporal entre las manifestaciones y la ingesta de la droga.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.